Wolfie, do you understand why the lenders ownership was limited to 9.9%?

Do you think that was part of your "creeping takeover plan"?

Wolfie states that Provista is still developing the lung cancer test from Radient.

What source would an astute investor use? An old press release or the current website from Provistadx?

Obviously, Wolfie is using the old press release.

b_b, most of the posts about a merger is just people who invested a lot of money and are stuck in the stock. The posts are just made up and easily proven wrong.

As for the value of DR70/onko sure as a cancer marker, it has been on the market in some fashion for about 14 years and has never produced enough sales to cover manufacturing costs. Most doctors in the USA consider universal markers like DR70 not worth the time, effort or money for the test. It failed here, failed in Canada, failed in Europe, failed in Australia, failed in China and failed in India. There is a small following in SE Asia and that has been the bulk of the meager sales the product had.

Next time this stock bumps on some sort of rumor, anyone with any smarts at all should dump.

It looks like the SEC certainly helped Provista "dodge a bullet"

"Provista and Radient also are in merger talks. They signed an extension Sept. 27, 2010 to give Radient’s shareholders a chance to set a meeting date for approval. Radient is publicly traded and must abide by U.S. Sec-ur-ities and Exchange Commission regulations.

“They’ve been filing different reports, and their shareholder meeting keeps getting delayed,” Gartner said. “They have to respond to SEC comments. That’s the only thing that’s holding up their shareholder approval of our merger.”


Radient was attempting to get the PRE14A shareholder meeting material approved and could not justify the value they had placed on Jade. If Provista had in fact merged with Radient, they would be dead also.

http://www.bizjournals.com/phoenix/print-edition/2010/11/12/provista-developing-early-test.html?page=all

Is your statement a joke?

"What I really think William meant in his comment in 2010 was that we had to wait for the SEC Hearings with the Rosen case..."

In 2010, Rosen wasn't even suing Radient and MacLellan had not even yet lied about the Mayo clinic working with Onko Sure.

Wolfie, you are wrong. Teamed up does not mean products were combined. Radient and Provista life sciences did in fact "team up" and work with the test. Radient was supposed to do all the testing of DR70 in smokers and former smokers. When the merger was terminated, Provista contined with the project but continued to delay quarter by quarter is supposed introduction.

I called Provista in 2011 and the LC Sentinel test was a test for fibrin degradation products in the blood of smokers and former smokers.

That is all the test was. No combinations, nothing else.

When Gartner transferred the property to Provisadx, LC Sentinel was one of the products transferred. All of the memory products were transferred to memorydx, a company owned and headed by Gartner since the memory patents were owned by Gartner.

Later, Gartner was given the LC Sentinel product and he formed GCDx and renamed the product "the lung cancer test".

Wolfie, The lung cancer test is not a combination of DR70 and anything else. It is just DR70 testing testing the fibrin decomposition in smokers and former smokers.

Since you are claiming it to be a combination test, then please tell us what the combination is and be specific. What patented test is it combined with?

That's a though question Wolfie because there is no combined test.

A couple years ago, one of the posters here actually contacted one of the lenders and surprisingly, he was open about what was happening. I think it was whalehaven.

Here's what happened to the RXPC and Provista life sciences merger.

1. Provista never even provided the paperwork for the merger.

2. Radient gave them $100,000 to provide the paperwork.

3. Provista took the $100,000, kept it and still never provided any merger materials.

4. Radient wrote off the $100,000 note as a BAD DEBT.

"On August 27, 2010, the Company advanced $95,000 to Provista Diagnostic, Inc. (“Provista”), as a note receivable. In addition, the note included $5,000 in origination fees. In connection with the note receivable agreement, Provista agreed to deliver two separate research reports to the Company by September 30, 2010 as full satisfaction of the balance owed. If the reports were not delivered to the Company by September 30, 2010, the agreement called for a 25% increase in the principal balance. Due to Provista’s failure to deliver such reports by September 30, 2010, the Company recorded interest income of $26,327, which represents the 25% increase from the principal balance of the note plus accrued interest of $1,062. If the research reports were not delivered to the Company by September 30, 2010, then the note required five equal payments of $20,000 (totaling $100,000) on the 1st day of each month commencing on the initial interest payment date (as defined in the note) and continuing thereafter until maturity (August 27, 2011). Interest accrued on the unpaid principal balance at a rate of 12% per annum until September 30, 2010. After this date, if the reports were not delivered interest began to accrue at the rate of 18% per annum.

On October 8, 2010, the required research reports were provided to the Company as satisfaction on the principal of the note. The accrued penalty and interest of $33,046 remains unpaid as of December 31, 2010. In the light of the overall economic crisis, our intended long-term relationship going forward with Provista, and the fact that as of the date of this report the balance was not collected, the Company considered the balance uncollectible and reversed the remaining balance against interest income as of December 31, 2010."

Dcspka, give us just one single example of an secret "creeping takeover".

Dcspka stated: " RXPC has not even publicly acknowledged the Rosen lawsuit. After the final closure of this unnecessary affair "

If you really think this was an unnecessary affair, then you need to read the legal proceedings again. Mac lied, and lied and lied and lied.

Regardless of all the ridiculous postings about takeovers, etc, the true situation is that Radient has no future whatsoever.

There will never be any reverse merger with Radient because of the massive debt that would have to be resolved. Radient owes over 20 million and the sale of 4.5 billion shares by the lenders only got them a couple hundred thousand dollars. The lenders notes are all still due and payable. Even the preferred shares they had were to be redeemed in cash back in 2012.

There will NEVER be any reverse merger with Radient.

Regardless of what some attempt to post, the lenders have no significant number of shares in Radient. If they did, they would file form 13's. The lenders would file the form 13's, not Radient and the lenders are very, very careful about remaining current with SEC rules.

I have posted the facts about the patents. Nothing should be confusing to anyone reading my posts.

Radient has two approved patents for DR70. One has already expired and the second will expire in just over a month.

Radient has one patent application that is in the pool for review which will take years. The application was rejected for "prior art". Smith-Howard argued that the GenWay art was not applicable but did nothing to refute the other prior art but to state that is was not applicable also.

Gartner has filed no patents on the DR70/LC Sentinel lung cancer test. There is nothing in the European database, the USA database nor the PCT WIPA filing system. Any filing he might make about DR70 and lung cancer would certainly be ruled "prior art" because of all the disclosures by Radient and the fact that it was approved by Health Canada for lung cancer testing already.

Wolfie is just dreaming about any connection between UNI and GCDx.

Since Radient made the SEC filing for the cancellation of the deal with Gartner and GCDx, then I would have expected to see a filing for the cancellation of the UNI deal if in fact it was cancelled. Since there was no filing and UNI is in fact distributing onko sure in SE Asia, the agreement is in effect.


Any statement otherwise is just hogwash.

Again Dcspka, If you were correct about the agreement with UNI being cancelled, why did Radient not file an 8k stating that agreement was cancelled?

Dcspka, Radient does not have to make any further disclosures about the UNI agreement unless it is cancelled.

Radient certainly disclosed the GCDx agreement was cancelled. Why would Radient not file that the UNI agreement was cancelled?

Dcspka, Radient does not have to make any announcement of payments from UNI. They are required to file annual and quarterly reports to the SEC which would have included the payments but Radient has not filed any financial reports for over two years.

So what is your proof that Radient did not pay. UNI is clearly distributing Onko Sure in SE Asia. They are not selling a generic version, it is ONKO SURE.

Wolfie, you did not answer why you think the UNI agreement was not finalized?

Wolfie, what makes you think the UNI agreement is currently not in force? There were indeed a SEC filing stating the GCDx agreement was cancelled but nothing has been filed to cancel the UNI agreement. In fact, there are several websites in SE Asia that are selling Onko Sure distributed by UNI.

What would be your proof that the agreement was never finalized? Dreams? Magic crystal ball? Imagination?

Wolfie, Do you understand what a cancelled agreement is?

You stated: "The only thing is BOTH have non compete and confidentiality clauses in BOTH agreements for 5 years"

The non compete and confidentiality portions are in the agreement that is cancelled when the last issued patent expires. They are not separate agreements. The UNI license agreement will be cancelled effective Jun 3, 2014 unless Radient has their patent application approved before that date and that isn't going to happen.

Wolfie, AGAIN you are wrong.

From the cancelled agreement with GCDx'

"This Agreement shall become effective upon the date of signing by both Parties and continue in effect until the earlier to occur of: (i) expiration of the last patent issued to RXPC for the Licensed Products,"

As soon as the last patent expires, all obligations are cancelled under the agreement and GCDx would be free to make any amount of DR70 and sell the same.

Wolfie, you are wrong again.
Gartner has no patent nor any patent application regarding "the lung cancer test" nor LC Sentinel nor DR70.

He has two applications in progress with the uspt. One is a mold test kit and I don't think you can stretch that one into a lung cancer test.

20080070244 Mold test kit

The other is a test for neurological disease. I also doubt you can stretch that one into a lung cancer test.

20030113701 Self-scoring method and apparatus for early self-screening of neurological disease

Wolfie, you are wrong again. In just over a month, the UNI agreement will be cancelled because the last remaining patent on DR70 is going to expire.

At that point, both license agreements will have been cancelled but both also have been given the technology to manufacture the test themselves so they can both make generic test kits with no need for any royalty payments at all.

Dcspka, William Gartner's plan in 2010/2011 was to merge Provista Life Sciences with Radient. That all fell through when Radient fell on its sword and Gartner went to plan B and sold the licenses of the breast and ovarian cancer markers to a new company called Provista diagnostics.

After Provista Diagnostics was created, a group of new investors wanted different management and dumped Gartner. Gartner was then no longer interested in a merger with a defunct Radient and made the deal to get all the know how for his LC Sentinel / The lung Cancer Test and license from Radient.

At this point, there would be no need or interest in a merger with Radient where he would take on more than 20 million in debt.

Any wild theories that Radient has any value remaining for any type of deal is just hogwash. In just over a month, there will be no patent left and a license deal for peanuts was made with UNI that will expire in just over a month.

Do you find any current listing of Gartner with Provista diagnostics?

http://www.azbio.org/azbio-board-of-directors/william-gartner

It is certainly not listed in his current bio.

As of 2012, Gartner was no longer on the scientific board for Provista diagnostics.

"Scottsdale, AZ, June 28, 2012 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a provider of oncology-based diagnostic tests and clinical laboratory services to the pharmaceutical and biotechnology industries, announced today the formation of a Scientific Advisory Board (SAB) comprised of recognized leaders in the fields of oncology and biomarker research. The SAB, which includes physicians and medical researchers, will provide critical strategic input on scientific, clinical, product development and commercialization matters.

"Provista is proud to have assembled such an impressive group of renowned scientists from the medical and research community. Their vast experience will be advantageous in not only guiding our current activities but also in evaluating and developing future opportunities," said Dr. David E. Reese, President and Chief Executive Officer of Provista. Dr. Reese further commented, "To have brought together such a highly esteemed group to serve on our Scientific Advisory Board is a validation of the importance of the company's mission and our development of cancer diagnostics."

Scientific Advisory Board Members

Karen Anderson, M.D., Ph.D.

Dr. Anderson, a clinical translational research scientist with an extensive research background, is an Associate Professor in Biodesign's Virginia G. Piper Center for Personalized Diagnostics at Arizona State University. In addition to her work at Biodesign, Dr. Anderson has a joint appointment with the Mayo Clinic Arizona as a medical oncologist with a specialization in breast cancer. Her research focuses on the development of immunodiagnostics and immunotherapies for cancer and has developed specific immune-based biomarkers for the early detection of breast, ovarian, and HPV-associated cancers. Dr. Anderson earned her M.D., Ph.D. from Duke University School of Medicine, and completed a residency in internal medicine at Brigham and Women's Hospital with a training fellowship in hematology/oncology at Dana-Farber Cancer Institute.

Carlos L. Arteaga, M.D.

Carlos L. Arteaga, a renowned medical oncologist who currently serves as Associate Director for Clinical Research and Director of the Breast Cancer Program of the Vanderbilt-Ingram Cancer Center and is Professor of Medicine and Cancer Biology in the Division of Hematology-Oncology at Vanderbilt. Dr. Arteaga is the recipient of several honors and awards andhas been widely published, credited with over 200 publications in the areas of oncogene signaling as well as the development of molecular therapeutics in breast cancer. Dr. Arteaga obtained his medical degree from the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University and the University of Texas Health Sciences Center in San Antonio, respectively.

Robert Benezra, Ph.D.

Dr. Benezra is a Member at Memorial Sloan-Kettering Cancer Center in the Department of Cell Biology and a Professor of Biology at Cornell Graduate School of Medical Sciences in New York City. Before joining Sloan-Kettering, Dr. Benezra worked at Fred Hutchinson Cancer Center in Seattle where he identified the Id proteins as dominant negative regulators of the helix-loop-helix protein family and has since gone on to identify these proteins as key regulators of tumor growth, angiogenesis and metastasis. Dr. Benezra obtained his Ph.D. from Columbia University in New York.

Andrew Dannenberg, M.D.

Dr. Dannenberg, the Henry R. Erle, MD-Roberts Family Professor of Medicine, is Director of the Weill Cornell Cancer Center. Dr. Dannenberg received his medical degree from Washington University in St. Louis and served as a medical resident and fellow at The New York Hospital-Cornell Medical Center. His laboratory is focused on elucidating the mechanisms underlying the inflammation-cancer connection with an emphasis on prostaglandin biology. Dr. Dannenberg has authored more than 150 scientific articles, as well as edited several books and journals. In 2011, he was awarded the American Association for Cancer Research-Prevent Cancer Foundation award for excellence in cancer prevention research. He is a member of the Association of American Physicians (AAP), the American Society for Clinical Investigation (ASCI), and the American Association for Cancer Research. He previously chaired the Program Committee of the AACR "Frontiers in Cancer Prevention Research" meeting and serves on the editorial boards of several journals including Cancer Prevention Research and Journal of Clinical Oncology.

J oshua LaBaer, M.D., Ph.D.

Dr. LaBaer is considered one of the nation's foremost investigators in the rapidly expanding field of personalized medicine, including the discovery and validation of biomarkers. Dr. LaBaer serves as the Virginia G. Piper Chair of Personalized Medicine and directs The Biodesign Institute, Personalized Diagnostics at Arizona State University. Formerly, he was founder and director of the Harvard Institute of Proteomics. Dr. LaBaer is a member of the National Cancer Institute's Board of Scientific Advisors and serves as chair of the National Cancer Institute's Early Detection Research Network Executive Committee and Co-Chair of its Steering Committee. Dr. LaBaer holds a BS from the University of California, Berkeley and earned his medical degree and a doctorate in biochemistry and biophysics from the University of California School of Medicine, San Francisco.

Provista Diagnostics invites interested readers to visit our website at www.provistadx.com to find out more about the Company and our technology.

About Provista Diagnostics, Inc.

Provista Diagnostics, Inc., a Delaware company, develops and commercializes breakthrough, easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company's focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exists. Near term development and commercialization efforts focus on women's cancers such as breast and ovarian cancer.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Provista Diagnostics, Inc.

Investor Relations:
John Fermanis

(602) 224-5500

Also in 2012, Gartner was ousted from the board of directors.

" Members of the Company's Board of Directors are Anne Busquet, Jeffrey R. Gilman, Robert J. Hariri M.D., Ph.D., Jack Levine CFA, John Macaskill, David E. Reese, Ph.D. and John Zicarelli Ph.D., FCAS, CFA."

Provista has NOTHING to do with GCDx nor anything at all to do with Radient. All of the stuff you are posting about a current connection with Radient is just hogwash.

Whoa Wolfie, you are wrong again. The filings you mention were in 2010. Gartner was dumped by Provista in 2012.

Do you see Gartner ANYWHERE on the current list of management at Provista? No, he is GONE.



Provista Companion Diagnostics (ProvistaCDx) is Your Partner in Clinical Assay Development, Molecular Diagnostics Development and Companion Diagnostic Approaches.





Team: Key Members of our Team


David E. Reese, Ph.D.

Current Role(s): President, Chief Executive Officer and Chief Scientific Officer

Dr. Reese was appointed as CEO in August of 2011. In these dual roles, Dr. Reese oversees executive management as well as scientific and regulatory affairs. As CSO, Dr. Reese is actively engaged in the ProvistaCDx process from a scientific, regulatory and analytical perspective.

Prior Experience:
?Managing Director at multiple asset management firms focused on emerging healthcare companies.

Education:
?Ph.D. in Biomedical Sciences, Vanderbilt University
?BS in Microbiology, Arizona State University



Sherri Borman, Ph.D.

Current Role(s): Vice President Laboratory Operations, Laboratory Director

Prior Experience: Dr. Borman brings to ProvistaCDx over 19 years' extensive training, education and experience performing and overseeing the testing in all areas of the laboratory to assure the highest level of quality possible fulfilling the regulatory requirements for the laboratory with a proven record of CLIA, CAP, GLP and OSHA successful inspections.

Education:
?Ph.D. in Physiological Sciences, University of Arizona
?BS in Nutritional Sciences (Minor Chemistry), University of Arizona


Meredith Henderson, Ph.D.

Current Role(s): Head of Research and Development and Provista Diagnostics, Inc Reference Laboratory (PDxRL) Lead Scientist

Prior Experience: Dr. Henderson brings an extensive knowledge of cancer development & progression, cancer genetics, and cancer biomarkers to her projects. While at TGEN, she characterized multiple serum biomarkers in pancreatic cancer utilizing cutting edge molecular techniques.

Education:
?Ph.D. in Cancer Biology, University of Arizona
?BA in Biology, New College of Florida


Crista Corn, MD

Current Role(s): Medical Director

Prior Experience: Dr. Corn brings over 25 years clinical experience and is responsible for consulting with the laboratory’s clients concerning test interpretation, establishing medical protocols, overseeing medical content, and acting as a medical interface with technology partners and communicating test result quality. Dr. Corn is currently the Director of the Breast Care Center of Arizona.

Education:
?University of Texas Medical School at Houston Doctor of Medicine
?BS in Chemistry, Baylor University, Waco, TX


Kim James, MT

Current Role(s): QA and Technical Supervisor

Prior Experience: Kim James is a board certified Medical Technologist through the American Society for Clinical Pathology (ASCP) with over 30 years’ experience performing and overseeing testing in all areas of the laboratory including sample handling, Quality Control, Quality Assurance, and instrument maintenance and troubleshooting.

Education:
?BS in Medical Microbiology, Long Beach State University, Long Beach, CA .

Think what you want but investors came in with a lot of money and magically, Gartner was GONE. Any logical person would understand the new investors did not want Gartner still running the company.

He was dumped/removed from the position of control. That is about as factual as you can get.

Just the COLD HARD FACTS.

Wolfie, Wow, you are so WRONG again.

Gartner did not have any patents that were sold, owned, bought or used by Provista.

"Provista Licenses Markers from Biodesign Institute to Support Breast, Ovarian Cancer"

When you cannot get ANYONE to invest in GDDx, it it obvious that something is WRONG. Most investors with money are not stupid and don't gamble investing in a company when the product does not have a successful history. If you are a stupid investor, you don't have your money very long. Investing in Radient is a dumb decision and investing in GCDx would be a dumb decision.

Gartner was dumped by the new investors at Provista. It was obvious that the new investors wanted more successful management and Gartner was not even included in the ownership of the new company.

Gartner was NOT bought out as you stated, new money came into the company and Gartner was no longer was in control nor did he get a share of the new investment money.

Wolfie, that was EXACTLY the time GCDx was formed. Gartner was dumped as CEO of Provista and he obviously thought the failed DR70 test had some sort of value even if it had been dropped by Provista.

Gartners failed attempt at financing the LC Sentinel/DR70 test is strong evidence that everyone else but Gartner has a low opinion of any success in marketing a DR70 lung cancer test.

This is also the same time period when Gartner was removed as CEO of Provista. It is obvious the new management at Provista did not think DR70/LC Sentinel was a viable product.

This was the LAST press release where Provista mentioned their DR70 renamed lung cancer test. Shortly thereafter, LC Sentinel was dropped from their website.

"SCOTTSDALE, Ariz., May 2, 2012 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a provider of oncology-based diagnostic tests and clinical laboratory services to the pharmaceutical and biotechnology industries, is pleased to announce the opening of its new 13,611 sq. ft. laboratory. The newly remodeled facility, located in Scottsdale, Arizona, will house the Provista Dx Reference Laboratory, an innovative, leading-edge CLIA accredited laboratory that is also GLP compliant.

Provista Diagnostics, Inc. develops and commercializes proprietary blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. Through the Provista Dx Reference Laboratory, the company offers a wide range of clinical diagnostic services, as well as, research contracting and biopharmaceutical testing to third parties throughout the United States. The Provista Dx Reference Laboratory, secured on a long-term lease, is both larger and superior to the site that it currently utilizes and provides a platform for further expansion of the services that can be offered. The new facility, which is both CLIA-accredited and GLP capable, is licensed in 45 states to perform human clinical testing and will offer a comprehensive menu of testing services, including custom projects.

"The move to this state-of-the-art facility clearly demonstrates the level of commitment that Provista is making to our customers and to the level of recent investments made in the company," said Dr. David Reese, President and CEO of Provista Diagnostics, Inc.

With the opening of the new facility, the company is also pleased to announce that Dr. Sherri Borman, Ph.D., HCLD/CC has joined Provista Diagnostics as its Clinical Laboratory Director. Dr. Borman, who has an extensive background in reproductive medicine and women's health, will be responsible for all clinical laboratory functions in the Provista Dx Reference Laboratory, including quality control, methodologies and certification. Dr. Borman is board certified both as a High-complexity Clinical Laboratory Director (HCLD) and a Clinical Consultant (CC) through the American Board of Bioanalysis (ABB) along with a Technical Supervisor (TS) board certification in Embryology, Andrology and Endocrinology. She has a Ph.D. in Physiological Sciences from the University of Arizona. Dr. Borman completed her NIH Post-Doctoral Fellowship at the Oregon Health & Science University in women's reproductive health. Most recently, Dr. Borman served as Laboratory Director for Kronos Science Laboratory, a position she had held since February 2009.

About Provista Diagnostics, Inc.

Provista Diagnostics, Inc., a Delaware company, develops and commercializes breakthrough, easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company's focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exists. Near term development and commercialization efforts focus on women's cancers such as breast and ovarian cancer, as well as early detection testing for lung cancer."

Below is the trademark link to the failed attempt of GenWay to market DR-70 in 2010 as a multi cancer test.

http://tsdr.uspto.gov/#caseNumber=77822922&caseType=SERIAL_NO&searchType=statusSearch

Check the specimen box and download their information.

The patent application you referenced was abandoned by Radient 5 years ago after a rejection by the USPT.

"The Lung Cancer Test" cannot be trademarked because,

1. USPT said it was too generic.

2. It has never been used in commerce.

GCDX has never marketed anything and probably never will.